Cover Image
Market Research Report

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2017

Published by GlobalData Product code 331738
Published Content info 95 Pages
Immediate Delivery Available
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2017
Published: November 16, 2017 Content info: 95 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q3 2017 with 1,077 deals worth USD90.3 billion, as compared 1,113 worth USD114.1 billion in Q3 2016. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2017, when compared to 1,153 deals worth USD92.3 billion in Q2 2017. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD347.3m in Q3 2017, as compared USD753.8m in Q3 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q3 2017, when compared to USD735.8m in Q2 2017. Deals in oncology therapeutics market registered a decrease with 362 deals in Q3 2017, compared to 392 deals in Q2 2017. North America reported a decrease in the number of deals from 726 in Q2 2017 to 676 in Q3 2017.

Scope:

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy:

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
Product Code: GDHC0520QD

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2017

  • 2.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2017
  • 2.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2017
  • 2.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2017
  • 2.4. Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2017
    • 2.4.1. Gilead Sciences Acquires Kite Pharma for USD11.9 Billion
    • 2.4.2. AstraZeneca Enters into Agreement with Merck
    • 2.4.3. Baotou Dongbao Bio Tech to Raise up to USD5.6 Billion in Private Placement of Shares
    • 2.4.4. Sanofi Enters into Licensing Agreement with Ablynx
    • 2.4.5. Gilead Sciences Raises USD3 Billion in Public Offering of Notes

3. Pharmaceuticals & Healthcare, Global, Deals Summary, by Type

  • 3.1. Pharmaceuticals & Healthcare, Global, M&A, Q3 2017
    • 3.1.1. Top M&A Deals in Q3 2017
    • 3.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2016-Q3 2017
  • 3.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2017
    • 3.2.1. Top Initial Public Offerings in Q3 2017
    • 3.2.2. Top Secondary Offerings in Q3 2017
    • 3.2.3. Top PIPE Deals in Q3 2017
    • 3.2.4. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2016-Q3 2017
  • 3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2017
    • 3.3.1. Top Venture Financing Deals in Q3 2017
    • 3.3.2. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2017
    • 3.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2017
    • 3.3.4. Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2016-Q3 2017
    • 3.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2016-Q3 2017
    • 3.3.6. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2016-Q3 2017
  • 3.4. Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2017
    • 3.4.1. Top Private Equity Deals in Q3 2017
    • 3.4.2. Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2016-Q3 2017

4. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2017

  • 4.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2017
  • 4.2. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2016-Q3 2017
  • 4.3. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017
    • 4.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2017
    • 4.3.2. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2017
    • 4.3.3. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2017
  • 4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016-Q3 2017
  • 4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2016-Q3 2017
  • 4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2016-Q3 2017
  • 4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016-Q3 2017

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2017

  • 5.1. Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2017
  • 5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016-Q3 2017
    • 5.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2017
    • 5.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2017
    • 5.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2017
  • 5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2016-Q3 2017
  • 5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2016-Q3 2017
  • 5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2016-Q3 2017
  • 5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2016-Q3 2017
  • 5.7. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2016-Q3 2017

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

  • 6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2017
    • 6.1.1. Oncology-Deals of the Quarter
  • 6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2017
    • 6.2.1. Central Nervous System-Deals of the Quarter
  • 6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2017
    • 6.3.1. Infectious Disease-Deals of the Quarter
  • 6.4. Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2017
    • 6.4.1. Immunology-Deals of the Quarter
  • 6.5. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2017
    • 6.5.1. Metabolic Disorders-Deals of the Quarter
  • 6.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2017
    • 6.6.1. Cardiovascular-Deals of the Quarter
  • 6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2017
    • 6.7.1. Gastrointestinal-Deals of the Quarter
  • 6.8. Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders Deals, Q3 2017
    • 6.8.1. Musculoskeletal Disorders-Deals of the Quarter
  • 6.9. Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2017
    • 6.9.1. Respiratory-Deals of the Quarter
  • 6.10. Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2017
    • 6.10.1. Dermatology-Deals of the Quarter

7. Deal Summary by Geography

  • 7.1. Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2017
    • 7.1.1. North America-Deals of the Quarter
  • 7.2. Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2017
    • 7.2.1. Europe-Deals of the Quarter
  • 7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2017
    • 7.3.1. Asia-Pacific-Deals of the Quarter
  • 7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2017
    • 7.4.1. Rest of the World-Deals of the Quarter

8. Pharmaceuticals & Healthcare, Global, Top Advisors

  • 8.1. Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2016-Q3 2017
  • 8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2016-Q3 2017

9. Further Information

  • 9.1. Methodology
  • 9.2. About GlobalData
  • 9.3. Contact Us
  • 9.4. Disclosure information
  • 9.5. Disclaimer

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2017
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2017
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2017
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2016 - Q3 2017
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2017
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2017
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2017
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2017
  • Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2017
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2016 - Q3 2017
  • Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2017
  • Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2017
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2017
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2017
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2017
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2017
  • Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2016 - Q3 2017
  • Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 46: Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2017
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2017
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2016 - Q3 2017
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2016 - Q3 2017
  • Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2017
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2017
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2016 - Q3 2017
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2016 - Q3 2017
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2016 - Q3 2017
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 36: Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
  • Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017
Back to Top